FB101 Intervention in Women Screened to Have Vaginal Dysbiosis (Dyscover-3)

Launched by FREYA BIOSCIENCES APS · Apr 28, 2023

Keywords

ClinConnect Summary

The Dyscover-3 clinical trial is investigating how a product called FB101 can help balance vaginal flora in healthy women who have been found to have an imbalance, known as vaginal dysbiosis. This condition can occur when the normal bacteria in the vagina are disrupted, which can affect women's health. The study aims to understand how the vaginal microbiome, which is the community of microorganisms in the vagina, changes after using FB101.

To participate in this trial, women need to be between the ages of 18 and 45, pre-menopausal, and generally healthy. They must also meet specific criteria related to their vaginal microbiome. Participants will undergo two procedures to receive the FB101 product and will need to provide some vaginal samples during the study. It's important for participants to follow certain guidelines, such as avoiding vaginal intercourse and certain products during the trial period. If you're interested in learning more or think you might qualify, consider reaching out to the study team for more information.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Be able and willing to give written informed consent.
• • Age between ≥18 to ≤45.
• • Be generally healthy, as determined by the investigator.
• • Be a pre-menopausal woman.
• • Meet the following definition of vaginal dysbiosis: combined copy number of Lactobacillus species crispatus, gasseri, and jensenii measured by qPCR, corresponding to less than 10% total relative abundance of Lactobacillus species crispatus, gasseri, and jensenii as measured by metagenomic sequencing.
• • Have regular, predictable menstrual cycles of known length or have been amenorrhoeic for at least 3 months due to use of a long-acting progestin or hormonal contraceptives.
• • Be willing to be asked questions about personal medical, sexual, and behavioural history.
• • Be willing to undergo two vaginal microbiome transplant procedures.
• • Be willing to self-collect cervicovaginal secretions and vaginal swab samples.
• * Be willing to use one of the following effective methods of contraception throughout the clinical study:
• • Complete abstinence from vaginal intercourse.
• • Have a male sexual partner who is surgically sterilised prior to the screening visit and is the only male sexual partner for that participant.
• • Mechanical barrier (condom or diaphragm), or hormone contraception (contraceptive pill, injections, implant or patch).
• • Be willing to completely abstain from vaginal intercourse and receptive oral sex during the eight days from visit 4 (first FB101 dose) to visit 6 (first follow-up).
• • Be willing to abstain from vaginal intercourse, unless using condoms free from adjunctive spermicide or lubricant (with a male partner) or dental dams (with a female partner), and receptive oral sex, unless using dental dams, in the time period between visit 3 and visit 8.
• • Be willing to avoid taking baths, swimming, or sitting in a hot tub in the time period between visit 3 and visit 8.
• • Be willing to abstain from using insertive vaginal feminine products (i.e., tampons, menstrual cups), vaginal cleansing products, spermicides, lubricants, or other vaginal products not approved by the study investigators, and any penetration using fingers or sex toys into the vagina, in the time period between visit 3 and visit 8.
• Exclusion Criteria:
• • Participants who are post-menopausal, defined as more than 12 consecutive months of amenorrhea without another known cause than use of long-acting progestin or hormonal contraceptives.
• • Participants who are pregnant, breastfeeding and/or have been pregnant within the last two months.
• • Users of any hormonal or non-hormonal intrauterine device (IUD).
• • Participants who have HIV/AIDS or other immunodeficiency.
• • Participants who test positive at screening for HIV, chlamydia, gonorrhoea, Mycoplasma genitalium, and/or Trichomonas vaginalis. Potential participants may be re-screened if they receive successful treatment at their own medical provider.
• • Participants who have received treatment involving experimental drugs less than 30 days prior to this study.
• • Participants who have undergone some sort of procedure involving trauma to the cervix within the last month prior to screening (i.e., IUD removal, cervical cryotherapy, or cervical laser treatment).
• • Participants with any known condition requiring regular use of antibiotics, that would suggest the participant is likely to require antibiotic treatment during the study.
• • Systemic and/or vaginally applied antibiotic use within the last month prior to screening.
• • Participants with new (\<3 months) use of long-acting hormonal treatments. Participant may be enrolled if stable (\>3 months) or existing therapy as determined by the investigator.
• • Participants with any social, medical, or psychiatric condition that in the opinion of the investigator would make it unlikely for the participant to comply with the study or would complicate interpretation of data from her participation.
• • Participants with a history of drug or alcohol abuse that in the opinion of the investigator would make it unlikely for the participant to comply with the study or would complicate interpretation of data from her participation.
• • Participants with a history of gynaecological cancers, gynaecological conditions, or surgical gynaecological medical history, which, in the opinion of the investigator, precludes participation.
• • Participants with abnormal finding on screening examination, which, in the opinion of the investigator, precludes participation.
• • Participants with clinically relevant abnormalities in the cervix or uterine cavity that could interfere with the collection of endometrial fluid.
• • Participants with history of hypersensitivity/allergic reactions to the antiseptic active component or its ingredients.
• • Participants who have previously received FB101 as part of a clinical study.